Covid Vaccine Race

The Advisory Committee on Immunization Practices voted 10-4 with 1 abstention to resume the rollout and administration of the Janssen shot.

Providing support to communities of color could encourage participation and improve uptake.

New analysis of registry data suggest pregnant persons are not facing particularly worse pregnancy nor neonatal outcomes after mRNA vaccination.

Two cases in the United States showed reinfection after administration of the m-RNA vaccines may complicate protection against new variants, but lend support to a potential need for a booster.

The Johnson & Johnson shot showed an efficacy of 66.9% and 66.1% on the 2 primary endpoints, with a higher efficacy against severe-critical disease.

Federal regulators authored a 12 page report citing several examples of misconduct within the plant, including improperly trained employees.

Severe blood clots reported with 2 COVID-19 vaccines are rare, but possible heightening of vaccine hesitancy would lower floodgates to pandemic waves

The committee stressed that the events are exceedingly rare, and that the vaccine's benefits outweigh the potential risks.

A cardiology expert discusses the unique and currently investigated relationship between COVID-19, adenovirus vaccines, and thrombotic events.

Pathologic antibodies to platelet factor 4 in patients who developed clots after the AstraZeneca vaccine indicates treatment include non-heparin anticoagulant.

The 2 shot mRNA vaccine has a high efficacy against COVID-19, but long term data for its protection is not there yet, and emerging variants may present a challenge.

Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met today to discuss the blood clots’ issue and offered guidance on heparin usage in these cases.

An interventional cardiologist discusses the observed cases of cerebral venous thrombosis in women administered the Johnson & Johnson COVID-19 vaccine.

Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.

The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

Despite a growing number of cases, millions gather in India for Hindu festival.

With millions of people vaccinated for COVID-19, A new study, collecting data from CDC's v-safe program, discusses reactions following mRNA-based vaccines.

The company asked the Food and Drug Administration (FDA) to amend their Emergency Use Authorization (EUA) to include 12-15 year olds.

The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.

A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency is making this recommendation for people in this age group after rare blot clots occurred after administration of the AstraZeneca vaccine.

The preclinical study showed that intranasal administration of OMV-Spike protected against the SARS-CoV-2 virus.

mRNA-1273 was seen to elicit antibodies for COVID-19 180 days following full dosage in a phase 1 trial and is still recommended for use by the authors.

The crossover will allow all trial participants to receive the vaccine while remaining blinded.

India recorded over 100,000 cases on Sunday, the countries highest daily total ever.